AN2 Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.9%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$1.05next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Investments Quarterly85.3MTarget: Sufficient to fund operations into 2029
Quarterly Net Loss Quarterly-10MTarget: Minimize cash burn through strategic pipeline prioritization
Watch Items
- Phase 2 clinical trial initiation of oral epetraborole in polycythemia vera (PV)Trigger: Initiation planned for Q3 2026Action: Monitor patient enrollment, sentinel safety group data, and dose titration outcomes.
- Phase 2 proof-of-concept study initiation for oral AN2-502998 in chronic Chagas diseaseTrigger: Initiation planned for late 2026Action: Review Phase 1 first-in-human and non-human primate enabling data reported in Q2 2026.
- Investigator-initiated Phase 2 trial of epetraborole in Mycobacterium abscessus lung diseaseTrigger: Trial active with 84 planned patientsAction: Track enrollment progress and site engagement; expect data readouts in late 2027.
Research as of 20 Jun 2026